Link William J Phd
Director at TARS; Director at RXST; Director at Oyster Point Pharma, Inc., and 3 more
- Sold, on record
- $38.3M
- Dollars the filings state
- Form 4 sales
- 18
- Latest Sep 15, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 6
- Filed as an executive or holder
Companies
- TARSTarsus Pharmaceuticals, Inc.Director
- RXSTRxSight, Inc.Director
- Oyster Point Pharma, Inc.Director
- GKOSGLAUKOS CorpDirector
- EWEdwards Lifesciences CorpDirector
- INTRALASE CORPDirector
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Oyster Point Pharma, Inc.550,000 shares
- INTRALASE CORP300,000 shares
- GKOS155,558 shares
- TARS122,562 shares
- EW50,792 shares
- RXST28,250 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Oyster Point Pharma, Inc.UnusualOct 18 2021
Sold 550,000 shares at $14.83 ($8.2M)
Link William J Phd, Director
Sold 99.1% of holdings ($8.2M position)4,987 shares leftFirst sale on recordFiling
- 2 Form 4 sale RXSTUnusualFeb 1 +836 days
Sold 28,250 shares at $49.67 ($1.4M)
Link William J Phd, Director
No 10b5-1 planSold 53.8% of holdings ($2.6M position)24,248 shares leftFirst sale on recordFiling
- 3 Form 4 sale TARSUnusualAug 12 +193 days
Sold 35,000 shares at $26.08 ($913k)
Link William J Phd, Director
No 10b5-1 planSold 100% of holdings ($913k position)0 shares leftFirst sale on recordFiling
- 4 Form 4 sale TARSNo planSep 8 +392 days
Sold 27,116 shares at $57.00 ($1.5M)
Link William J Phd, Director
No 10b5-1 planSold 15.9% of holdings ($9.7M position)143,332 shares leftFiling
- 5 Form 4 sale TARSRoutineDec 15 +98 days
Sold 22,946 shares at $81.26 ($1.9M)
Link William J Phd, Director
10b5-1 planSold 15.1% of holdings ($12.3M position)128,832 shares leftFiling
- 6 Form 4 sale TARSRoutineMar 16 +91 days
Sold 12,500 shares at $68.79 ($860k)
Link William J Phd, Director
10b5-1 planSold 9.7% of holdings ($8.9M position)116,332 shares left0.5x usual sizeFiling
- 7 Form 4 sale TARSRoutineJun 15 +91 days
Sold 12,500 shares at $62.12 ($776k)
Link William J Phd, Director
10b5-1 planSold 10.5% of holdings ($7.4M position)106,786 shares left0.5x usual sizeFiling
- 8 Form 4 sale TARSRoutineSep 15 +92 days
Sold 12,500 shares at $78.38 ($980k)
Link William J Phd, Director
10b5-1 planSold 11.7% of holdings ($8.4M position)94,487 shares left0.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (18)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TARS | Director | Form 4 sale | 12,500 | $980k | 11.7% | Routine | SEC |
| Jun 15, 2026 | TARS | Director | Form 4 sale | 12,500 | $776k | 10.5% | Routine | SEC |
| Mar 16, 2026 | TARS | Director | Form 4 sale | 12,500 | $860k | 9.7% | Routine | SEC |
| Dec 15, 2025 | TARS | Director | Form 4 sale | 22,946 | $1.9M | 15.1% | Routine | SEC |
| Sep 8, 2025 | TARS | Director | Form 4 sale | 27,116 | $1.5M | 15.9% | No plan | SEC |
| Aug 12, 2024 | TARS | Director | Form 4 sale | 35,000 | $913k | 100.0% | Unusual | SEC |
| Feb 1, 2024 | RXST | Director | Form 4 sale | 28,250 | $1.4M | 53.8% | Unusual | SEC |
| Oct 18, 2021 | Oyster Point Pharma, Inc. | Director | Form 4 sale | 550,000 | $8.2M | 99.1% | Unusual | SEC |
| Dec 1, 2020 | GKOS | Director | Form 4 sale | 50,000 | $3.4M | 76.4% | Unusual | SEC |
| Aug 21, 2019 | EW | Director | Form 4 sale | 10,214 | $2.3M | 50.8% | Unusual | SEC |
| Nov 19, 2018 | EW | Director | Form 4 sale | 13,578 | $2M | 69.2% | Unusual | SEC |
| Nov 15, 2018 | GKOS | Director | Form 4 sale | 41,500 | $2.4M | 50.6% | Unusual | SEC |
| Feb 9, 2018 | EW | Director | Form 4 sale | 12,000 | $1.5M | 42.9% | Unusual | SEC |
| Nov 29, 2016 | EW | Director | Form 4 sale | 15,000 | $1.3M | 34.9% | Unusual | SEC |
| Nov 17, 2016 | GKOS | Director | Form 4 sale | 30,000 | $1M | 25.5% | Unusual | SEC |
| May 31, 2016 | GKOS | Director | Form 4 sale | 34,058 | $817k | 23.7% | Plan not stated | SEC |
| Jan 12, 2007 | INTRALASE CORP | Director | Form 4 sale | 250,000 | $6.1M | 10.4% | Plan not stated | SEC |
| May 9, 2006 | INTRALASE CORP | Director | Form 4 sale | 50,000 | $1M | 2.0% | Plan not stated | SEC |